BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Healthtrust
Federal Trade Commission
Mallinckrodt
Fish and Richardson
UBS
McKesson
Fuji
Covington
Cipla

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,585,897

« Back to Dashboard

Which drugs does patent 7,585,897 protect, and when does it expire?

Patent 7,585,897 protects APLENZIN and is included in one NDA.

This patent has forty-nine patent family members in seventeen countries.
Summary for Patent: 7,585,897
Title:Modified release formulations of a bupropion salt
Abstract:The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
Inventor(s): Oberegger; Werner (Mississauga, CA), Zhou; Fang (Davie, FL), Maes; Paul (Toronto, CA), Jackson; Graham (Co. Kildare, IE), Saleh; Mohammad Ashty (Oakville, CA)
Assignee: Biovail Laboratories International S.r.l. (St. Michael, BB)
Application Number:11/766,239
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form;

Drugs Protected by US Patent 7,585,897

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-001 Apr 23, 2008 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-002 Apr 23, 2008 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-003 Apr 23, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,585,897

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,569,611 Modified release formulations of a bupropion salt ➤ Subscribe
7,662,407 Modified release formulations of a bupropion salt ➤ Subscribe
7,241,805 Modified release formulations of a bupropion salt ➤ Subscribe
7,645,802 Bupropion hydrobromide and therapeutic applications ➤ Subscribe
8,932,628 Modified release formulations of a bupropion salt ➤ Subscribe
8,354,453 Bupropion hydrobromide and therapeutic applications ➤ Subscribe
7,671,094 Bupropion hydrobromide and therapeutic applications ➤ Subscribe
7,884,136 Modified-release formulations of a bupropion salt ➤ Subscribe
9,504,640 Modified release formulations of a bupropion salt ➤ Subscribe
7,553,992 Modified release formulations of a bupropion salt ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,585,897

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Singapore 183695 ➤ Subscribe
Russian Federation 2485943 ➤ Subscribe
Russian Federation 2010107843 ➤ Subscribe
Russian Federation 2485942 ➤ Subscribe
Russian Federation 2010116863 ➤ Subscribe
Russian Federation 2408368 ➤ Subscribe
Russian Federation 2007147343 ➤ Subscribe
New Zealand 582925 ➤ Subscribe
New Zealand 561375 ➤ Subscribe
Mexico 2010003872 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
McKesson
Accenture
Dow
Novartis
Boehringer Ingelheim
Medtronic
Harvard Business School
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot